GP
BLUE

GLG Partners’s bluebird bio BLUE Stock Holding History

GLG Partners’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$2M Buy
+868
New +$1.76M 0.09% 225

Other funds holding BLUE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

GLG Partners's BLUE Position: Q4 2017 in Review

GLG Partners opened a new position in bluebird bio (BLUE) in Q4 2017: 868 shares worth $2M. The stake represents 0.09% of the portfolio and ranks #225 among its holdings.

296 funds tracked by Wall St. Rank hold BLUE as of Q4 2017.

  • GLG Partners held 868 shares of bluebird bio worth $2M as of Q4 2017.
  • bluebird bio was a new GLG Partners position in Q4 2017.
  • bluebird bio made up 0.09% of GLG Partners's portfolio in Q4 2017, its #225 holding.
  • 296 funds tracked by Wall St. Rank held bluebird bio as of Q4 2017.

Based on GLG Partners's 13F filing for Q4 2017, filed 14 Feb 2018.